Funder
National Institute of Neurological Disorders and Stroke
National Institutes of Health
Reference72 articles.
1. Ketamine for depression, 1: clinical summary of issues related to efficacy, adverse effects, and mechanism of action;Andrade;J. Clin. Psychiatry,2017
2. The dissociative anaesthetics, ketamine and phencyclidine, selectively reduce excitation of central mammalian neurones by N‐methyl‐aspartate;Anis;Br. J. Pharmacol.,1983
3. Long-term effect of sub-anesthetic ketamine in reducing l -DOPA-induced dyskinesias in a preclinical model;Bartlett;Neurosci. Lett.,2016
4. Preclinical evidence in support of repurposing sub-anesthetic ketamine as a treatment for L-DOPA-induced dyskinesia;Bartlett;Exp. Neurol.,2020
5. Highly-selective μ-opioid receptor antagonism does not block L-DOPA-induced dyskinesia in a rodent model;Bartlett;BMC Res. Notes,2020